A Phase 3 interventional study of Golimumab 100 mg and Golimumab 50 mg in Rheumatoid Arthritis, sponsored by Centocor, Inc.. Completed at 52 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-29.
Sponsored by Centocor, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing golimumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. golimumab · Arthritis, Rheumatoid.
Among the 16 studies testing golimumab in Arthritis, Rheumatoid, this one is the 6th largest by enrollment, is one of 2 that started in 2005, is one of 11 in phase 3, and was the 2nd registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 16 studies testing golimumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
golimumab: first FDA approval 2009 (SIMPONI), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 444 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 356 across the 16 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 8 most frequent:
This study is registered under Centocor, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Centocor, Inc. is the lead sponsor of 75 studies on the registry; none are open to participants now.
90 studies in Arthritis, Rheumatoid by Johnson & Johnson: 1 open now, 1 under way, none of them phase 3. Of 86 finished, 31 (36%) have results posted.
Among the 90 studies in Arthritis, Rheumatoid by Johnson & Johnson, this one is the 13th largest by enrollment of the 75 interventional ones that give a count, is one of 5 that started in 2005, is one of 20 in phase 3, and was the 15th registered.
Johnson & Johnson’s Arthritis, Rheumatoid studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing golimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 90 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate (MTX), as compared to methotrexate alone in rheumatoid arthritis (RA) patients who have active rheumatoid arthritis despite treatment with MTX.
This is a randomized (treatment is assigned by chance), double-blind (neither the physician nor the patient is aware of the received treatment), placebo-controlled study of multiple subcutaneous (SC) administrations of golimumab at 2 doses as monotherapy or in combination with MTX in patients with active RA despite treatment with MTX. The duration of participation in the study for an individual patient will be upto 268 weeks. The patients will be randomly assigned in a 3:3:2:2 ratio to receive golimumab 50 mg or 100 mg or placebo injections under the skin every 4 weeks through week 20 and methotrexate or placebo capsules will be given in addition. At Week 24, all subjects will receive golimumab 50mg or 100mg injections, and golimumab continues for all groups for about 4 and a half more years. At Week 16 any patient in the study who meets criteria for \< 20% improvement from baseline in both swollen and tender joint count will enter early escape in a double-blinded fashion. Treatment during the long-term extension will start at Week 52 and continue every 4 weeks thereafter for a total of approximately 5 years from the initial (Week 0) administration of study agent. Patients will return for scheduled follow-up visits generally every 12 weeks for a total length of follow-up of approximately 5 years from the first administration of the study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo subcutaneous (SC) injections every 4 weeks from Week 0 to Week 20 (early escape at Week 16); Methotrexate - 15 to 25mg weekly from Week 0 up to 5 yrs; Golimumab - if early escape, 50mg SC injections every 4 weeks from Week 16 up to 5 years; Golimumab - 50 mg SC injections every 4 weeks from Week 24 up to 5 yrs (unless early escape); Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
Drug: Methotrexate · Drug: Placebo injection
Golimumab 100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Placebo - 7-10 capsules weekly during blinded period (or Week 16 if early escape); Methotrexate - if early escape, 15 to 25mg weekly from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
Drug: Golimumab 100 mg · Drug: Placebo capsules
Golimumab 50 mg SC injections every 4 weeks from Week 0 up to 5 yrs (unless early escape at Week 16); Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
Drug: Golimumab 50 mg · Drug: Methotrexate
Golimumab100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
Drug: Golimumab 100 mg · Drug: Methotrexate
Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.
Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.
Participants will receive methotrexate capsules weekly.
Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
Participants will receive placebo capsules weekly
Number of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 14
ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain of pain by the Visual Analogue Scale (VAS) (0-10 cm) b.Patient's Global Assessment of Disease activity VAS (0-10 cm) c. Physician's Global Assessment of Disease Activity VAS (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein.
Time frame: Week 14
Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 24
HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).
Time frame: Baseline (Week 0) and Week 24
Number of Participants With Disease Activity Index Score 28 (DAS 28) Using C-reactive Protein (CRP) Response at Week 14
DAS 28 using CRP is an index to measure the disease activity in participants with rheumatoid arthritis which combines tender joint count (28 joints), swollen joint count (28 joints), CRP value, and participant's global assessment of disease activity (using a Visual Analog Scale of 0 to 100 mm). The DAS 28 score ranges from 0 (best) to 10 (worst). Participants are considered to have a DAS 28 response if they have a score of \<= 3.2 (good response) or \> 3.2 to 5.1 (moderate response).
Time frame: Week 14
Number of Participants Who Achieved American College of Rheumatology 20 (ACR 20) Response at Week 24
An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain (VAS) (0-10 cm) b.Patient's Global Assessment of Disease activity (VAS) (0-10 cm) c. Physician's Global Assessment of Disease Activity (VAS) (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein (CRP).
Time frame: Week 24
Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 14
The HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).
Time frame: Baseline (Week 0) and Week 14
Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24
The vdH-S score is the sum of joint erosion score and joint-space narrowing (JSN) score. The total score ranges from 0 (best) to 448 (worst) with higher scores indicating more joint damage.
Time frame: Baseline (Week 0) and Week 24
A total of 444 participants were enrolled at 60 sites in 12 countries.
| Milestone | Group 1: Placebo + Methotrexate | Group 2: Golimumab 100 mg + Placebo | Group 3: Golimumab 50 mg + Methotrexate | Group 4: Golimumab 100 mg + Methotrexate |
|---|---|---|---|---|
| Started | 133 | 133 | 89 | 89 |
| Completed | 90 | 92 | 72 | 59 |
| Not completed | 43 | 41 | 17 | 30 |
| Withdrew: Death | 0 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 1 | 1 | 1 |
| Withdrew: Adverse event | 23 | 18 | 9 | 14 |
| Withdrew: Unsatisfactory therapeutic effect | 4 | 11 | 4 | 6 |
| Withdrew: Discontinued oral study agent | 0 | 1 | 0 | 0 |
| Withdrew: Other | 13 | 7 | 3 | 9 |
ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain of pain by the Visual Analogue Scale (VAS) (0-10 cm) b.Patient's Global Assessment of Disease activity VAS (0-10 cm) c. Physician's Global Assessment of Disease Activity VAS (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein.
| Participants | Group 1: Placebo + Methotrexate | Group 2: Golimumab 100 mg + Placebo | Group 3: Golimumab 50 mg + Methotrexate | Group 4: Golimumab 100 mg + Methotrexate | Combined Golimumab + Methotrexate |
|---|---|---|---|---|---|
| Number of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 14 | 44 | 59 | 49 | 50 | 99 |
DAS 28 using CRP is an index to measure the disease activity in participants with rheumatoid arthritis which combines tender joint count (28 joints), swollen joint count (28 joints), CRP value, and participant's global assessment of disease activity (using a Visual Analog Scale of 0 to 100 mm). The DAS 28 score ranges from 0 (best) to 10 (worst). Participants are considered to have a DAS 28 response if they have a score of \<= 3.2 (good response) or \> 3.2 to 5.1 (moderate response).
| Participants | Group 1: Placebo + Methotrexate | Group 2: Golimumab 100 mg + Placebo | Group 3: Golimumab 50 mg + Methotrexate | Group 4: Golimumab 100 mg + Methotrexate | Combined Golimumab + Methotrexate |
|---|---|---|---|---|---|
| Number of Participants With Disease Activity Index Score 28 (DAS 28) Using C-reactive Protein (CRP) Response at Week 14 | 67 | 84 | 64 | 67 | 131 |
HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).
| Units on a scale | Group 1: Placebo + Methotrexate | Group 2: Golimumab 100 mg + Placebo | Group 3: Golimumab 50 mg + Methotrexate | Group 4: Golimumab 100 mg + Methotrexate | Combined Golimumab + Methotrexate |
|---|---|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 24 | 0.1250 (-0.1250 to 0.3750) | 0.1250 (-0.2500 to 0.6250) | 0.3750 (0.1250 to 0.7500) | 0.5000 (0.1250 to 0.7500) | 0.4375 (0.1250 to 0.7500) |
An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain (VAS) (0-10 cm) b.Patient's Global Assessment of Disease activity (VAS) (0-10 cm) c. Physician's Global Assessment of Disease Activity (VAS) (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein (CRP).
| Participants | Group 1: Placebo + Methotrexate | Group 2: Golimumab 100 mg + Placebo | Group 3: Golimumab 50 mg + Methotrexate | Group 4: Golimumab 100 mg + Methotrexate | Combined Golimumab + Methotrexate |
|---|---|---|---|---|---|
| Number of Participants Who Achieved American College of Rheumatology 20 (ACR 20) Response at Week 24 | 37 | 47 | 53 | 53 | 106 |
The HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ score which ranges from 0 (no disability) to 3 (completely disabled).
| Units on a scale | Group 1: Placebo + Methotrexate | Group 2: Golimumab 100 mg + Placebo | Group 3: Golimumab 50 mg + Methotrexate | Group 4: Golimumab 100 mg + Methotrexate | Combined Golimumab + Methotrexate |
|---|---|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 14 | 0.1250 (-0.1250 to 0.3750) | 0.2500 (-0.1250 to 0.6250) | 0.3750 (0.1250 to 0.7500) | 0.3750 (0.1250 to 0.6250) | 0.3750 (0.1250 to 0.7500) |
The vdH-S score is the sum of joint erosion score and joint-space narrowing (JSN) score. The total score ranges from 0 (best) to 448 (worst) with higher scores indicating more joint damage.
| Units on a scale | Group 1: Placebo + Methotrexate | Group 2: Golimumab 100 mg + Placebo | Group 3: Golimumab 50 mg + Methotrexate | Group 4: Golimumab 100 mg + Methotrexate | Combined Golimumab + Methotrexate |
|---|---|---|---|---|---|
| Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24 | 0.00 ± 2.354 | 0.00 ± 1.598 | 0.00 ± 2.740 | 0.00 ± 1.342 | 0.00 ± 2.159 |
Collected over Adverse event data were collected for 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Golimumab 50 mg SC Injections Only | — | 33/105 (31.4%) | 96/105 (91.4%) |
| Group 2: Golimumab 100 mg SC Injections Only | — | 84/184 (45.7%) | 160/184 (87%) |
| Group 3: Golimumab 50 and 100 mg SC Injections | — | 55/145 (37.9%) | 118/145 (81.4%) |
| Event | Group 1: Golimumab 50 mg SC Injections Only | Group 2: Golimumab 100 mg SC Injections Only | Group 3: Golimumab 50 and 100 mg SC Injections |
|---|---|---|---|
| Rheumatoid ArthritisMusculoskeletal and connective tissue disorders | 2/105 | 6/184 | 5/145 |
| CholelithiasisHepatobiliary disorders | 0/105 | 5/184 | 3/145 |
| SepsisInfections and infestations | 1/105 | 5/184 | 1/145 |
| CellulitisInfections and infestations | 1/105 | 4/184 | 1/145 |
| Basal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/105 | 4/184 | 1/145 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/105 | 3/184 | 3/145 |
| Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/105 | 0/184 | 3/145 |
| GoitreEndocrine disorders | 2/105 | 0/184 | 2/145 |
| PneumoniaInfections and infestations | 2/105 | 3/184 | 2/145 |
| Squamous Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/105 | 2/184 | 2/145 |
| Event | Group 1: Golimumab 50 mg SC Injections Only | Group 2: Golimumab 100 mg SC Injections Only | Group 3: Golimumab 50 and 100 mg SC Injections |
|---|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 39/105 | 64/184 | 39/145 |
| CoughRespiratory, thoracic and mediastinal disorders | 24/105 | 35/184 | 14/145 |
| BronchitisInfections and infestations | 18/105 | 27/184 | 28/145 |
| NasopharyngitisInfections and infestations | 15/105 | 35/184 | 24/145 |
| PharyngitisInfections and infestations | 13/105 | 20/184 | 25/145 |
| DiarrhoeaGastrointestinal disorders | 16/105 | 24/184 | 11/145 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 16/105 | 18/184 | 15/145 |
| HypertensionVascular disorders | 8/105 | 25/184 | 21/145 |
| Urinary Tract InfectionInfections and infestations | 9/105 | 20/184 | 20/145 |
| Back PainMusculoskeletal and connective tissue disorders | 10/105 | 22/184 | 20/145 |
| Age, Continuous(years) | Group 1: Placebo + Methotrexate | Group 2: Golimumab 100 mg + Placebo | Group 3: Golimumab 50 mg + Methotrexate | Group 4: Golimumab 100 mg + Methotrexate | Total |
|---|---|---|---|---|---|
| Mean | 51.2 ± 11.96 | 50 ± 11.47 | 50.3 ± 10.98 | 50 ± 10.78 | 50.4 ± 11.36 |
| Sex: Female, Male(Participants) | Group 1: Placebo + Methotrexate | Group 2: Golimumab 100 mg + Placebo | Group 3: Golimumab 50 mg + Methotrexate | Group 4: Golimumab 100 mg + Methotrexate | Total |
|---|---|---|---|---|---|
| Female | 109 | 105 | 72 | 72 | 358 |
| Male | 24 | 28 | 17 | 17 | 86 |
The record gives a start of Dec 2005, a primary completion of Sep 2007 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 6 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Golimumab · Methotrexate